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Background: A key issue in the treatment of obesity in older adults is whether the health 
benefits of weight loss outweigh the potential risks with respect to musculoskeletal injury.
Objective: To compare change in weight, improvements in metabolic risk factors, and reported 
musculoskeletal adverse events in middle-aged (50–59 years) and older (65–74 years), obese 
women.
Materials and methods: Participants completed an initial 6-month lifestyle intervention for 
weight loss, comprised of weekly group sessions, followed by 12 months of extended care with 
biweekly contacts. Weight and fasting blood samples were assessed at baseline, month 6, and 
month 18; data regarding adverse events were collected throughout the duration of the study.
Results: Both middle-aged (n = 162) and older (n = 56) women achieved significant weight 
reductions from baseline to month 6 (10.1 ± 0.68 kg and 9.3 ± 0.76 kg, respectively) and 
maintained a large proportion of their losses at month 18 (7.6 ± 0.87 kg and 7.6 ± 1.3 kg, 
 respectively); there were no significant differences between the two groups with respect to weight 
change. Older women further experienced significant reductions in systolic blood pressure, 
HbA
1c
, and C-reactive protein from baseline to month 6 and maintained these improvements at 
month 18. Despite potential safety concerns, we found that older women were no more likely 
to experience musculoskeletal adverse events during the intervention as compared with their 
middle-aged counterparts.
Conclusion: These results suggest that older, obese women can experience significant health 
benefits from lifestyle treatment for obesity, including weight loss and improvements in disease 
risk factors. Further investigation of the impact of weight loss on additional health-related 
parameters and risks (eg, body composition, muscular strength, physical functioning, and 
injuries) in older adults is needed.
Keywords: lifestyle intervention, adverse events, metabolic risk factors
Introduction
According to reports from the National Health and Nutrition Examination 
 Survey (NHANES), the prevalence of obesity in women 60 to 79 years is 42.3% 
(95% confidence interval [CI]: 38.3%–46.3%), compared with a prevalence of 31.9% 
(95% CI: 28.6%–35.5%) in women aged 20 to 39;1 as such, obesity among older 
women represents a serious public health problem. Obesity in this age group is strongly 
associated with diabetes, hypertension, dyslipidemia, and osteoarthritis,2 although the 
relation between obesity and all-cause mortality in this age group is inconsistent.3–6 
Independent of weight status, age is correlated with greater prevalence and severity 
of many obesity-related health conditions and metabolic risk factors.7 Additionally, 
obesity has been associated with significant impairment in health-related quality of 
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life in older individuals.8 However, excess weight in older 
 persons (65 years and older) may also offer protective benefits 
with respect to bone loss, osteoporosis, and hip fracture.9,10 
Further, some have noted the “obesity paradox,” whereby 
obesity has been found to be protective against mortality 
due to certain causes such as heart failure or cardiovascular 
disease.11,12
For middle-aged and young adults who are obese, the 
benefits of behavioral weight-loss treatment clearly outweigh 
potential risks. Reviews of randomized trials demonstrate 
that lifestyle interventions, typically delivered in weekly 
group sessions over the course of 4 to 6 months, produce 
average weight losses of 8.5 kg posttreatment (approximately 
5%–10% of initial body weight).13–15 Reductions of this 
magnitude can have beneficial effects on a variety of weight-
related health conditions and risk factors.16–18 However, sev-
eral longitudinal observational studies have demonstrated that 
weight loss in older adults is related to increased mortality, 
disability, functional limitation, institutionalization, loss of 
lean muscle mass and bone mineral density, increased risk of 
hip fracture, and loss of mobility.19,20 These studies, however, 
have not controlled for a number of potential confounds, such 
as intentionality of weight loss, obesity status prior to weight 
loss, occult disease or pathology, and smoking status.
A small number of clinical trials have been conducted to 
examine the effects of weight-loss treatment among older, 
obese adults,21–23 but a recent meta-analysis suggested that 
high-quality evidence regarding the efficacy of weight-loss 
interventions among older adults is lacking and that addi-
tional studies are needed.23 This meta-analysis also indicated 
that although obese, older adults are able to achieve signifi-
cant weight losses, changes in blood pressure, lipid profile, 
glycemic control, exercise capacity, and quality of life, as a 
consequence of weight-loss treatment, did not reach statistical 
significance. Moreover, data on these health outcomes were 
very limited, and there was substantial heterogeneity across 
studies.23 Adverse outcomes were not examined in this meta-
analysis, though results from the Diabetes Prevention Pro-
gram indicated that rates of musculoskeletal adverse events 
were slightly higher among the lifestyle intervention group 
as compared with the placebo (although authors reported 
no significant differences by treatment assignment).24 Older 
participants were more likely to report adverse events as 
compared with younger participants.24 In a recent random-
ized controlled clinical trial examining the effectiveness of 
diet, exercise, or a combination, among adults 65 years of 
age or older, Villareal et al22 reported that participants in the 
diet-only arm experienced reductions in lean body mass and 
bone mineral density, while participants in the exercise arm 
reported a greater degree of musculoskeletal injuries. This 
study also reported significant improvements in a variety of 
weight-related health outcomes.22 However, authors did not 
report whether these risks and benefits of weight-loss treat-
ment differed by age.
At present, it remains unclear whether the benefits of 
intentional weight loss in older, obese adults outweigh 
potential risks of weight-loss treatment, and whether 
improvements in health or risks associated with treatment are 
similar across age cohorts. Few studies have examined the 
effects of behavioral weight-loss treatment in older adults.10,25 
Intentional weight loss in older, obese adults could ameliorate 
weight-related diseases and conditions, such as joint pain, 
psychological symptoms, and quality of life,10 but could 
simultaneously present risks with regards to musculoskeletal 
injury, and bone and muscle loss.
The current study investigated both the health benefits 
(ie, weight loss, improvements in metabolic risk factors) 
and adverse consequences of weight-loss treatment in older 
adults (65–74 years) and examined whether these effects 
were comparable to those experienced by middle-aged adults 
(50–59 years). The primary aims of the present study were to 
determine: (1) if older, obese women experience significant 
benefits (ie, weight loss) from a lifestyle intervention for 
weight loss; (2) if behavioral weight-loss treatment is asso-
ciated with negative outcomes (ie, musculoskeletal injury) 
for older, obese women; and (3) if weight loss and adverse 
event outcomes are equivalent in older and middle-aged 
participants. We hypothesized that positive and adverse 
outcomes would be similar across age groups. A secondary 
aim of this study was to describe and compare the responses 
of older and middle-aged participants with regards to changes 
in metabolic risk factors, including systolic blood pressure, 
LDL cholesterol, Hemoglobin A
1c
, and C-reactive protein.
Materials and methods
This study is a secondary analysis of data collected in 
the TOURS (Treatment of Obesity in Underserved Rural 
Settings) trial. TOURS was a randomized, controlled trial 
of behavioral weight-loss treatment, in six medically under-
served rural counties in northern Florida, USA.26
Participants
Participants in the TOURS trial were 298 women (aged 
50–75 years), with body mass index (BMI) .30 kg/m2, who 
resided in rural counties in north-central Florida. Potential 
participants were excluded if they weighed over 158.8 kg, had 
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a history of heart attack or stroke, metabolic abnormalities, 
any musculoskeletal conditions that limited walking, any 
major psychiatric disorders, or experienced significant weight 
loss (ie, $4.5 kg) in the 6 months prior to the study.
Procedure
The University of Florida Institutional Review Board 
approved all study procedures. Recruitment and study meth-
ods have been described previously.26 At months 0, 6, and 18, 
participants’ weights and blood pressures were assessed, 
and blood was drawn and analyzed for metabolic profile. 
Participant height was measured at month 0 but not during 
the later assessment points.
Measures
Primary aims
Percent weight change
Weight was measured to the nearest 0.1 kilogram using a 
calibrated and certified balance beam scale. Participants 
were measured in light indoor clothing with shoes removed. 
Change in body weight was calculated by subtracting 
 participants’ 6 and 18 month weights from their baseline 
values. Participant height was measured, without shoes, to 
the nearest 1.0 cm using a portable stadiometer. Height and 
weight were used to calculate BMI.
Musculoskeletal adverse events
Participants were asked to report all adverse events experi-
enced throughout the duration of the study. Adverse events 
were categorized for review by a local Institutional Review 
Board and by a specially constituted Data Safety and 
Monitoring Board. Additionally, all events were separately 
recoded, as representing a musculoskeletal injury or other 
type of adverse event. Musculoskeletal adverse events were 
chosen because research has demonstrated a slight increase 
risk of this type of injury with lifestyle treatment.24
Secondary aim
Metabolic risk factors
Resting blood pressure was measured by a Registered Nurse 
(RN), using a standardized protocol.27 In the present study, 
only systolic blood pressure was examined due to its relation 
to cardiovascular disease risk.28 Similarly, lipid profile was 
measured using low density lipoprotein (LDL)-cholesterol 
due to its strong association with cardiovascular disease risk.29 
Glycemic control, which is highly related to diabetic risk,30 
was assessed via Hemoglobin A
1c
 (HbA
1c
), which is a more 
durable measure of glycemic control than  fasting  glucose.31 
C-reactive protein is a marker of  inflammation, which is 
associated with atherosclerosis and cardiovascular disease, 
and was also measured.32 Blood samples were drawn by 
the study RN and analyzed by Quest Diagnostics Clinical 
Laboratories (Quest Diagnostics Inc, Madison, NJ, USA) 
for lipid and metabolic profile.
TOURS intervention
All participants received a 6-month lifestyle intervention 
(Phase I) carried out through Cooperative Extension Service 
offices in six rural counties in North Florida. Phase I of the 
TOURS trial included 24 weekly group behavioral treatment 
sessions. The program was designed to decrease caloric 
intake (to 1200 kcal per day) and increase moderate-intensity 
physical activity to reach a 10,000 per day step average or 
attain at least 3000 steps greater than baseline levels. No 
liquid meal supplements were utilized in the trial. At the 
conclusion of Phase I, these women were randomized to 
one of three year-long follow-up programs with biweekly 
contacts (Phase II): a face-to-face counseling program, 
a telephone counseling program, or a mail-only education 
“control” condition.
Change in caloric intake  
and physical activity
Change in caloric intake was assessed using the Block Food 
Frequency Questionnaire (Block FFQ).33 This self-report 
questionnaire asks participants to record the frequency at 
which they consumed 106 different foods over the preceding 
year. This questionnaire probes participants for the portion 
size of foods consumed, along with composition (eg, low- vs 
high-fat cuts of meat) and added condiments (eg, butter or 
jam added to toast). Estimates from the Block FFQ have been 
demonstrated to correlate 0.45 with estimated “true” dietary 
intake using 24-hour recalls.34
Physical activity was measured using the CHAMPS 
Physical activity questionnaire for older adults.35 This 
40-item questionnaire was specifically designed to assess 
types of physical activity that are appropriate for older adults. 
The CHAMPS has been validated against other physical 
activity measures, with correlations of 0.73 for moderate-
intensity activities (which were the focus of the current 
intervention), and 0.55 for all specified activities.35
Statistical analyses
The data analyses were performed using both a per-protocol 
and an intent-to-treat approach. All randomized partici-
pants were included in the intent-to-treat analyses. For this 
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approach, multiple imputation was used to handle missing 
weights for individuals who dropped out after baseline;  values 
were imputed assuming weight was regained back at a rate 
of 0.3 kg per month.36,37 The variance of this distribution 
was chosen as the variance of the residual from regressing 
6-month (or 18-month) weights on baseline weight among 
those individuals without missing weights; this essentially 
corresponds to the variance under an assumption of missing 
at random (MAR). Use of this scenario is consistent with the 
findings from long-term studies of weight loss that show a 
reliable return to baseline weights over time and was used in 
the primary analysis of TOURS.26,38,39 For the metabolic risk 
factors, a similar multiple imputation approach was used, 
with means corresponding to the baseline value of the risk 
factor. For the equivalence tests, only treatment completers 
were used (a per-protocol approach). Use of only treatment 
completers is consistent with a recent Consolidated Standards 
of Reporting Trials (CONSORT) group statement regarding 
the appropriate use of equivalence testing.40 Use of intent-
to-treat analyses in equivalence testing can increase the risk 
of type I error, as it suppresses observed mean differences 
between groups. Statistical analyses were conducted using 
SPSS (v17.0 for Windows; IBM, Armonk, NY, USA) and 
SAS (v9.1.2 for Windows; SAS Institute Inc, Cary, NC, 
USA) software programs.
Primary aims: weight loss and adverse events
To determine if older, obese women experience significant 
benefits from a lifestyle intervention for weight loss, we fit 
multivariate normal regression models, controlling for race/
ethnicity, to examine changes in weight from month 0 to 
month 6 and month 18 using SAS Proc Mixed. Bonferroni cor-
rections were applied to adjust for multiple comparisons.
To assess whether weight change and number of adverse 
events were equivalent between middle-aged and older obese 
women, we used equivalence tests. Margins of equivalence 
(∆) for weight and the proportion of each group (older 
women and middle-aged women) reporting a musculosk-
eletal adverse event were set a priori, based on the smallest 
value that would represent a clinically significant difference. 
Weight outcomes for older and middle-aged participants were 
regarded as equivalent if the difference between group means 
(using a 95% CI of the difference) was less than or equal to 
2.5 kg. Similarly, the proportions of each group reporting a 
musculoskeletal adverse event were regarded as equivalent 
if the 95% CI of the difference was contained within ±∆ 
(±0.04). The mean difference in weight change between older 
and middle-aged groups was obtained using multivariate 
normal regression. CIs of the difference in proportions of 
older and middle-aged women reporting a musculoskeletal 
adverse event were calculated using methods described by 
Newcombe.41
Secondary aims: metabolic risk factors
Multivariate normal regression models fit using SAS Proc 
Mixed were used to compare older and middle-aged par-
ticipants with regards to changes in metabolic risk factors 
over time. Criterion variables included systolic blood pres-
sure, LDL-cholesterol, HbA
1c
, and C-reactive protein. To 
adjust for multiple comparisons, Bonferroni corrections 
were applied.
Results
Baseline characteristics by age
The mean age of participants in the TOURS study was 
59.3 ± 6.2 years. The present study included 56 older women 
(65–74 years) and 162 middle-aged women (50–59 years) 
drawn from the total sample. Among all 298 participants, 
75.5% classified their race/ethnicity as Caucasian, 20.5% 
as African American, 1.7% as Hispanic American, 2.0% as 
American Indian, and 0.3% as Pacific Islander. The mean 
pretreatment weight was 96.5 ± 14.9 kg, and mean baseline 
BMI was 36.8 ± 5.0 kg/m². The majority of the sample 
(64.4%) had completed at least 12 years of education, with 
43.3% reporting at least trade, vocational, or associate 
 training. The majority of participants were married (72.5%), 
and nearly half of the women were employed full or part time 
(47.3%). Over two-thirds of the sample (67.9%) reported a 
total household income of less than $50,000.
Older women (ie, women 60–74 years; n = 56) in this 
study were more likely to be Caucasian, χ²(1) = 4.6, P , 0.05, 
and less likely to be employed, χ²(1) = 57.2, P , 0.001, than 
middle-aged women (ie, women 50–59 years; n = 162). Older 
women weighed significantly less than middle-aged women 
at baseline, t(216) = 2.3, P , 0.025, but this difference was 
not clinically significant, and both groups fell in the Class II 
obesity range (BMI 35.0 to 39.9 kg/m²) at pretreatment. 
Older women did not differ from middle-aged women on any 
metabolic risk factor at pretreatment, with the exception of 
systolic blood pressure, which was higher in the older group, 
t(216) = -3.6, P , 0.001. Baseline characteristics by age are 
displayed in Table 1.
Previous analyses of the TOURS data have suggested 
that Caucasian women and African-American women 
respond differently to treatment in terms of magnitude 
of weight loss, changes in metabolic risk factors, and a 
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number of behavioral variables.42 The older age group was 
comprised of a significantly greater proportion of Caucasian 
women, thus equivalence testing was conducted separately 
for  Caucasian and African American women. However, 
given that the older age group contained only seven African 
American women, we did not have enough power to perform 
formal tests of equivalence with this subsample. Thus, only 
descriptive statistics are provided.
Weight change
Using a per-protocol analysis (ie, treatment completers 
only) we fit a multivariate normal regression to examine 
within-group changes in weight, while controlling for race/
ethnicity. The proportion of older women who completed 
the study was not significantly different from the proportion 
of middle-aged women, χ²(1) = 0.58, P = 0.466. Similarly, 
there were no significant differences between the propor-
tion of older and middle-aged women who returned for 
assessment at month 6 or month 18, (P = 0.948 and 0.467, 
respectively). There were also no significant differences 
between groups in reported caloric change from month 0 to 
month 6 for older and middle-aged women (-438.7 kcal/day 
vs -504.7 kcal/day, P = 0.645), although both groups 
experienced significant decreases in reported caloric intake 
over this time, t(51) = 4.5, P , 0.0001, and t(145) = 6.5, 
P , 0.0001, respectively. With respect to changes in 
reported physical functioning, while both older and middle-
aged women significantly increased their average distance 
walked from month 0 to month 6 (65.9 feet vs 71.8 feet, 
t[50] = 3.46, P , 0.001 and t[140] = 5.39, P , 0.0001, 
respectively), there was no significant difference between 
groups in this change, P = 0.812.
Older women evidenced a significant reduction in weight 
from month 0 to month 6, mean ± standard error (SE) = 
9.3 ± 0.76 kg, P , 0.001. This weight loss was largely main-
tained at month 18, at 7.6 ± 1.3 kg, P , 0.001. Similarly, middle-
aged women experienced a significant within-group weight loss 
from month 0 to month 6, mean ± SE = 10.1 ± 0.68 kg, and this loss 
was largely maintained at month 18, mean ± SE = 7.6 ± 0.86 kg. 
Changes in weight over time among treatment completers 
are displayed in Table 2. Using an  intent-to-treat approach 
produced similar results (Figure 1).
With respect to clinically signif icant weight loss 
(ie, weight loss $ 5% of baseline weight), there were no 
further differences by age group over time. At 6 months, 
78.8% of older adults achieved a $5% weight loss compared 
with 75.0% of middle-aged adults, χ2(1) = 0.312, P = 0.576; 
at 18 months, 57.1% of older women maintained a clinically 
significant weight loss compared with 51.1% of middle-aged 
women, χ2(1) = 0.530, P = 0.467.
Equivalence testing
Weight change
Among treatment completers, older Caucasian women 
(n = 47) lost a mean ± SE of 9.6 ± 0.83 kg from month 0 
Table 1 Baseline demographic characteristics of older and 
middle-aged participants
Older (65–74 years) 
n = 56
Middle-aged 
(50–59 years) 
n = 162
Mean ± SD
Age (years) 69.1 ± 2.9 54.6 ± 2.7
Percent of sample
Race/ethnicity (%)  
Caucasian 83.9 69.1
African American 12.5 25.9
Employment (%)
Full or part time 10.7 69.1
Retired 55.4 5.6
Not working 8.9 6.2
More than one category 19.6 9.9
Abbreviation: SD, standard deviation.
Table 2 Changes in weight and metabolic risk factors in older 
and middle-aged women (per-protocol analysis)
Mean ± SE
Older  
(65–74 years)
Middle-aged 
(50–59 years)
Weight (kg)
Month 0  92.7 ± 2.4  97.0 ± 1.2
Month 6  83.4 ± 2.5  86.9 ± 1.2
Month 18  85.1 ± 2.7a  89.4 ± 1.3a
Systolic BP (mm Hg)
Month 0 129.6 ± 1.2 124.3 ± 0.9
Month 6 122.3 ± 1.5 116.1 ± 1.0
Month 18 124.0 ± 2.0a 118.9 ± 1.2a
LDL-cholesterol (mg/dL)
Month 0 115.8 ± 4.2 123.7 ± 2.8
Month 6 122.3 ± 1.5 116.1 ± 1.0
Month 18 119.5 ± 6.0 122.5 ± 3.1
HbA1c (%)
Month 0   6.1 ± 0.1   5.9 ± 0.1
Month 6   5.8 ± 0.1   5.7 ± 0.1
Month 18   5.9 ± 0.1a   5.8 ± 0.1a
C-reactive protein (mg/dL)
Month 0   4.4 ± 0.8   6.5 ± 0.5
Month 6   2.3 ± 0.3   3.9 ± 0.3
Month 18   2.5 ± 0.4a   3.7 ± 0.4a
Notes: aIndicates significant within-group differences, P , 0.01.
Abbreviations: BP, blood pressure; LDL, low density lipoprotein; HbA1c, 
hemoglobin A1c; Se, standard error.
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to month 6, which was not significantly different from the 
11.0 ± 0.55 kg weight loss achieved by middle-aged  Caucasian 
women (n = 112). The 95% CI of the difference (-3.4 to 
0.55) was not contained within the margin of equivalence 
(2.5 kg), thus, statistical equivalence could not be established. 
At long-term follow up, older women had lost a mean of 
7.6 ± 1.3 kg body weight; again, this was not significantly 
different from the 7.4 ± 0.76 kg weight loss evidenced by 
middle-aged women. The groups were not equivalent with 
respect to weight loss at month 18, as the 95% CI of the dif-
ference exceeded the margin of equivalence (95% CI: -2.8 
to 3.2, respectively).
Older African American women (n = 7) lost a mean of 
5.9 ± 3.0 kg of body weight from month 0 to month 6, as 
compared with 6.7 ± 4.3 kg for the middle-aged African 
American women (n = 42). At long-term follow-up, older 
African American women had lost 6.1 ± 5.1 kg of body weight 
as compared with 5.0 ± 7.7 kg for the middle-aged women.
Adverse events
Point-biserial correlations indicated that there was no rela-
tionship between age (as a continuous variable) and the 
report of injury at 6 or 18 months (r = 0.05, P = 0.400, and 
r = 0.03, P = 0.630, respectively). During initial treatment 
(month 0 to 6), 23% of older Caucasian women reported 
at least one musculoskeletal adverse event, as compared 
with 18% of middle-aged Caucasian women. The 95% CI 
of the difference in proportions, calculated according to the 
methods described by Newcombe,41 was -20.6% to 7.2%, 
well outside the margin of equivalence (4%). The proportion 
of older women reporting a musculoskeletal adverse event 
over the course of the entire study (month 0 to 18) was 47%, 
as compared with 36% of middle-aged Caucasian women, 
χ²(1) = 1.7, P = 0.19. Again, the 95% CI of the difference in 
proportions fell outside the margin of equivalence (95% CI: 
-27.3 to 5.2).
To further investigate the risk of musculoskeletal injury, 
we divided all participants into ad hoc 5-year age cohorts. 
Although the sample of women over 70 years of age was not 
large enough to conduct a formal significance test (n = 16), 
56% of Caucasian participants over 70 years of age reported 
at least one adverse event over the course of the study as 
compared with 37% of Caucasian women ages 50 to 69 years 
(n = 209).
During initial treatment, 11% of older African-American 
women reported a musculoskeletal adverse event, as com-
pared with 26% of middle-aged women. At long-term fol-
low up, 42% of middle-aged African-American women had 
reported at least one adverse event, as compared with only 
11% of older African-American women. There was a trend 
for older African-American women to be less likely to report 
a musculoskeletal adverse event overall than middle-aged 
African-American women, χ²(1) = 3.1, P = 0.078, again a 
difference that may have reached significance with a larger 
sample size.
Secondary aims: metabolic risk factors
Using a per-protocol approach, older women experienced sig-
nificant reductions in systolic blood pressure from month 0 to 
month 6, mean ± SE = 7.3 ± 1.77, P , 0.001, and maintained 
75.0
80.0
85.0
90.0
95.0
100.0
Month 0 Month 6 Month 18
kg
Middle-aged (50–59 years)
Older (65–74 years)
Figure 1 Change in weight over time, adjusted for race/ethnicity (intent-to-treat analysis).
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these improvements at month 18, mean change ± SE month 
0 to 18 = 5.9 ± 1.8, P , 0.01. Changes in LDL cholesterol 
were not significant over time. HbA
1c
 was significantly reduced 
from month 0 to months 6, 0.32 ± 0.01, P , 0.001; and from 
month 0 to month 18, 0.25 ± 0.09, P , 0.01. C-reactive pro-
tein was also significantly reduced from month 0 to month 6, 
2.1 ± 0.63, P , 0.001; these changes were maintained at 
month 18, -2.0 ± 0.70, P , 0.01. Changes in metabolic risk 
factors over time can be seen in Table 2. Using an intent-to-treat 
approach, a similar pattern of results emerged (Figure 2).
Discussion
The present study examined both the benefits (ie, weight loss 
and improvements in metabolic risk factors) and adverse out-
comes of a lifestyle intervention for weight loss in a sample of 
older and middle-aged adults, and compared these outcomes 
between age groups. Older women achieved significant reduc-
tions in weight during treatment and at long-term follow up. 
Among treatment completers, older Caucasian women had 
lost a mean of 9.6 kg of body weight at 6 months, which 
was not statistically different from the 11.0 kg of weight loss 
achieved by middle-aged Caucasian women. At 18 months, 
the difference between older and middle-aged participants 
exceeded the margin of equivalence (7.5 vs 8.5 k g; 95% CI: 
-2.4 to 4.4), possibly due to the small sample size of older 
adults. A comparison of middle-aged and older African-
American women revealed a trend for older women to lose 
more weight than middle-aged women from baseline to month 
18 (6.1 kg of body weight as compared with 5.0 kg).
With regards to adverse outcomes, 23% of older 
 Caucasian women reported at least one musculoskeletal 
injury during initial treatment, and 47% reported this type of 
adverse event over the course of the 18-month intervention. 
These proportions were not significantly different from the 
18% of middle-aged women reporting an injury during initial 
treatment and the 36% reporting an injury throughout the 
18 month study. The Diabetes Prevention Program Research 
Group described a similar pattern of results for participants 
in the “lifestyle” condition, by which participants between 
60 and 85 years of age reported 28 musculoskeletal adverse 
events per 100 person-years, in contrast to 25 to 40 year old 
participants, who reported 20 musculoskeletal adverse events 
per 100 person-years, a nonsignificant difference.24
The proportions of middle-aged and older women report-
ing a musculoskeletal adverse event during initial treatment 
and over the course of the entire study were not equivalent. 
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Post hoc power analyses suggested we would have needed 
over 800 participants per group to determine equivalence, 
even if we had used a wider 10% margin. Beyond rejecting 
our hypothesis that older and middle-aged women experience 
comparable rates of injury, it appears that older Caucasian 
women may be at greater risk for injury than middle-aged 
Caucasian women. When we further categorized the sample 
into 5-year age increments, 56% of Caucasian women over 
70 years of age reported at least one musculoskeletal injury 
throughout the 18 months, as compared with only 37% of 
Caucasian participants 50 to 69 years of age. Given that only 
16 women fell into the above 70-year age range, we did not 
have enough power to examine differences in the proportion 
of women over 70 reporting a musculoskeletal injury, as 
compared with younger age groups. This discrepancy war-
rants further investigation regarding the safety of behavioral 
weight-loss treatment for older adults, with a larger sample. 
A related finding deserving of further investigation is the 
potential trend for older African-American women to report 
fewer adverse events than their younger counterparts. Future 
research with larger samples of racial and ethnic subpopula-
tions should examine these potential differences.
With respect to our secondary aims, older women experi-
enced a significant reduction in systolic blood pressure from 
pre- to posttreatment and largely maintained this decrease 
at 18 months. Additionally, older women showed significant 
reductions in HbA
1c
 and C-reactive protein from month 0 to 
month 6, and from month 0 to month 18. There was no sig-
nificant within-group change over time in LDL-cholesterol 
levels. Overall, the current results support the hypothesis that 
older women experience a number of benefits from lifestyle 
interventions for weight loss. However, the present study 
did not measure additional health-related parameters, such 
as medication use or changes in body composition, muscu-
lar strength, or physical functioning. While outcomes from 
weight loss in older adults hold both potential risks and ben-
efits,43 further investigation of these variables is warranted.
There are several limitations to the present study. First, 
we had a relatively small sample of older women, offering 
limited power to detect small differences in a variety of 
outcomes. A second limitation was the lack of an untreated 
control group of older women. Although there appeared to 
be a slight increase in risk of musculoskeletal injury for older 
women, we cannot determine if this increase was related to 
participation in the study or the consequence of aging. Future 
research should compare the rate of musculoskeletal injury 
in older women not undergoing weight-loss treatment with 
those participating in the lifestyle program, to clarify if this 
type of treatment is associated with greater risk of injury in 
older adults.
Additionally, individuals with serious health conditions 
(eg, uncontrolled diabetes or hypertension) were excluded 
from the study. Given that the severity of weight-related risk 
factors and diseases is typically compounded with age, the 
exclusion of older women with serious health conditions at 
baseline may have resulted in a sample that is not representa-
tive of the larger population of women over 65 years of age. 
Generalizability is also limited by the exclusion of younger 
age groups as well as the underrepresentation of older racial/
ethnic minority participants.
This study has several important implications with regards 
to the safety and efficacy of behavioral weight-loss interven-
tions for older adults. We found that older women (those 
over 65 years of age) experienced significant benefits from 
a lifestyle intervention for weight loss. However, results also 
indicated that older women might be at greater risk for mus-
culoskeletal adverse events during participation in a lifestyle 
intervention for weight loss as compared with their middle-
aged counterparts. Subsequently, lifestyle interventions 
including older adults should take particular precautions to 
educate participants about safe ways to achieve exercise goals 
and avoid injury (eg, including several supervised exercise 
sessions at initiation of treatment). Future research should 
further explore potential negative outcomes of weight-loss 
treatment for older, obese adults, particularly with respect to 
musculoskeletal injury, and bone and muscle loss.
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